Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nalu-0016
- Development stage
- Preclinical
- Lead developer
- Nalu Bio
- Modality
- Small Molecules
01
Overview
Nalu-0016 is a small molecule drug candidate developed by Nalu Bio, currently in the lead optimization stage of development. It is designed to target the endocannabinoid system (ECS), specifically modulating G protein-coupled receptors (GPCRs) within this system. While the specific molecular targets and primary therapeutic indications remain undisclosed, the program is part of Nalu Bio's broader effort to develop precision ECS-targeted therapies. The company focuses on utilizing chemistry to create high-quality, consistent compounds that interact with the ECS to address various health conditions without the psychoactive effects associated with natural cannabinoids.
02
Targets
CB (Cannabinoid receptors)
Beyond the preview
Go deeper on Nalu-0016.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nalu-0016.